NASDAQ: MNOVMedicinova Inc Stock
$1.51+0.00 (+0%)
Updated Dec 11, 2025
MNOV Priceïğż
$1.51
Fair Value Price
$0.82
Market Capïğż
$74.06M
52 Week Lowïğż
$1.13
52 Week Highïğż
$2.24
P/Eïğż
-6.04x
P/Bïğż
1.68x
P/Sïğż
241.45x
PEGïğż
N/A
Dividend Yieldïğż
N/A
Revenueïğż
$257.92k
Earningsïğż
-$12.01M
Gross Marginïğż
10.2%
Operating Marginïğż
-4,654.5%
Profit Marginïğż
-4,656.6%
Debt to Equityïğż
0.08
Operating Cash Flow
-$10M
Betaïğż
0.75
Next Earningsïğż
N/A
Ex-Dividendïğż
N/A
Next Dividendïğż
N/A
MNOV Overview
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNOV's potential to beat the market
- MNOV doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNOV
RankedUnranked of 489
RankedUnranked of 489
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $320.84 | A | |
| $20.62 | A | |
| $7.16 | A |
Be the first to know about important MNOV news, forecast changes, insider trades & much more!
MNOV News
Overview
Due Diligence Score
â
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNOV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNOV ($1.51) is overvalued by 84.38% relative to our estimate of its Fair Value price of $0.82 based on Discounted Cash Flow (DCF) modelling
Below Fair Valueïğż Valuation
MNOV ($1.51) is not significantly undervalued (84.38%) relative to our estimate of its Fair Value price of $0.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Valueïğż Valuation
MNOV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Valueïğż Valuation
There are 30 more MNOV due diligence checks available for Premium users.
Valuation
MNOV fair value
Fair Value of MNOV stock based on Discounted Cash Flow (DCF)
Price
$1.51
Fair Value
$0.82
Overvalued by
84.38%
MNOV ($1.51) is overvalued by... subscribe to Premium to read more.
Below Fair Valueïğż Valuation
MNOV ($1.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Valueïğż Valuation
MNOV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Valueïğż Valuation
MNOV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.04x
Industry
159.38x
Market
45.84x
MNOV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
5.34x
MNOV is good value based... subscribe to Premium to read more.
P/B vs Industryïğż Valuation
MNOV's financial health
Profit margin
Revenue
$123.3k
Net Income
-$3.1M
Profit Margin
-2,473.6%
MNOV's cash burn is expected... subscribe to Premium to read more.
Interest Coverageïğż Financials
MNOV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growthïğż Financials
Assets to liabilities
Assets
$47.6M
Liabilities
$3.6M
Debt to equity
0.08
MNOV's short-term assets ($32.92M) exceed... subscribe to Premium to read more.
Short-term Liabilitiesïğż Financials
MNOV's short-term assets ($32.92M) exceed... subscribe to Premium to read more.
Long-term Liabilitiesïğż Financials
MNOV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debtïğż Financials
MNOV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equityïğż Financials
Cash flow
Operating
-$1.7M
Investing
-$2.9k
Financing
$0.0
MNOV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverageïğż Financials
MNOV vs Biotech Stocks
Medicinova Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.